Epidemiology and Clinical Impact of Respiratory Coinfections at Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia
Romain Lécuyer(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Pascale Bémer, Antoine Roquilly, Karim Lakhal(Inserm), Jean Reignier(Centre Hospitalier Universitaire de Nantes), Frédéric Gabriel(Centre Hospitalier Universitaire de Bordeaux), David Boutoille, Antoine Asquier-Khati, Cédric Bretonnière(Inserm), Arnaud-Félix Miailhe(Inserm), Nahéma Issa(Bordeaux Population Health), Stéphane Corvec, Marie Chauveau(Inserm), J. Caillon(Nantes Université), Olivier Zambon, Emmanuel Canet, Céline Bressollette‐Bodin, Benjamin Gaborit(Institut Paoli-Calmettes), Anne‐Gaëlle Leroy, Raphaël Cinotti, F.–X. Blanc(Institut du Thorax), Rose‐Anne Lavergne(Centre d'Investigation Clinique de Nantes), P Morin(Albert Einstein College of Medicine), Patrice Le Pape, Colin Deschanvres(Inserm), Karim Asehnoune(Nantes Université), Benoît Tessoulin(Centre Hospitalier Universitaire de Nantes), R. Lecomte(Inserm), Fakhri Jeddi(Inserm), Florent Morio, Fabrice Camou(Hôpital Saint-André), Paul Le Turnier(Inserm), F. Raffi(Inserm), Charlotte Biron, A. Guillouzouic, Amélie Seguin, M. Lefèbvre(Inserm)
Cited by 36
Related Papers
The primary mechanism of attenuation of bacillus Calmette–Guérin is a loss of secreted lytic function required for invasion of lung interstitial tissue
|Proceedings of the National Academy of Sciences|2003|737
Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections
|European Journal of Vascular and Endovascular Surgery|2020|515
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
|Intensive Care Medicine|2021|420
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study
|Intensive Care Medicine|2017|309